EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
Price:
9.1 USD
-1.83%
Market Closed
Updated:
Jun 8, 2024
EyePoint Pharmaceuticals Inc
Change in Working Capital
|
EyePoint Pharmaceuticals Inc
Change in Working Capital Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Change in Working Capital Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Change in Working Capital
$43.2m
|
CAGR 3-Years
27%
|
CAGR 5-Years
77%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Change in Working Capital
-$94m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
15%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Change in Working Capital
-$356m
|
CAGR 3-Years
21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Change in Working Capital
-$5m
|
CAGR 3-Years
35%
|
CAGR 5-Years
69%
|
CAGR 10-Years
42%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Change in Working Capital
-$2.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-24%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Change in Working Capital
-$5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-33%
|
See Also
What is EyePoint Pharmaceuticals Inc's Change in Working Capital?
Change in Working Capital
43.2m
USD
43.2m
USD
Based on the financial report for Mar 31, 2024, EyePoint Pharmaceuticals Inc's Change in Working Capital amounts to 43.2m USD.
What is EyePoint Pharmaceuticals Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
77%
77%
Over the last year, the Change in Working Capital growth was 1 164%. The average annual Change in Working Capital growth rates for EyePoint Pharmaceuticals Inc have been 27% over the past three years , 77% over the past five years .
You don't have any saved screeners yet
